FDA Officials Discussed Aging Therapy Regulations in 2026

Agency leaders joined the Aging Research and Drug Discovery conference to address clinical trial mandates.

Updated on Oct. 3, 2026 in Biotech

Isometric editorial illustration of a glass beaker containing geometric biological structures, representing clinical trial biomarkers. — FDA officials and researchers discussed regulatory endpoints for longevity-focused clinical trials during the 2026 Aging Research and Drug Discovery conference. AI Illustration. Upload story photo >

Live Poll

Would you prioritize medical research that extends life expectancy over research that improves late-life health?

During the 2026 Aging Research and Drug Discovery conference, FDA officials met with experts to discuss regulatory requirements for testing longevity-focused therapeutics. The dialogue focused on overcoming the long duration of traditional clinical trials through the use of validated biomarkers.

Why it matters

Longevity researchers are working to find reliable ways to measure if interventions change aging processes, which would otherwise require decades-long studies. Establishing clear clinical endpoints is essential for the future development and approval of therapies targeting aging.

Researchers have developed more than 50 molecular aging clocks utilizing DNA changes, protein expression, and microbiome composition. Regulators currently require these metrics to prove defined clinical endpoints before any longevity therapy can be approved.

The players

Steven Kozlowski

He serves as the Chief Scientist at the FDA.

Jeffrey Siegel

He serves as the Director of the Office of Drug Evaluation Sciences.

Justin Penzenstadler

He serves as the Associate Director of the Office of Cardiology, Hematology, Endocrinology and Nephrology.

Lowell M. Zeta

He serves as the Acting Chief of Staff in the FDA Office of the Commissioner.

National Institute on Aging

This institute oversees research into molecular aging clocks and aging-related health.

The details

The FDA panel emphasized the necessity of validated biomarkers that demonstrate improvements in health or disease risk as a prerequisite for therapeutic development. Participants addressed how these measurable metrics serve as substitutes for long-term health outcomes in the context of clinical trials.

The Aging Research and Drug Discovery meeting occurred in 2026.
A scientific review of the previous ARDD meeting was published in 2025.

The Tech Race

The FDA's focus on clinical validation tracks the rapid proliferation of the National Institute on Aging's molecular aging clock research programs. This shift moves the industry away from observational data toward the strict regulatory frameworks required to bring aging-modifying drugs to market.

For the average person, these regulatory discussions influence how quickly potential anti-aging therapies may reach clinical testing stages. While these developments are currently in the scientific evaluation phase, they set the stage for future treatments that could eventually alter the standard of care for aging-related diseases.

The takeaway

The development of standardized biomarkers is a critical hurdle that must be cleared to accelerate the pace of longevity science. Readers should note that while the field is evolving rapidly, the translation of aging clocks into FDA-approved health interventions remains a long-term goal.